RNA-binding motif protein 10 represses tumor progression through the Wnt/β- catenin pathway in lung adenocarcinoma
| Autor: | Qingwei Meng, Yongxu Zhou, Jianxiong Geng, Bo Pan, Lishuang Qi, Yan Yu, Yingyue Cao, Zijie Wang, Xin Wang, Zixin Wei, Shi Jin, Yaoguo Lang, Shanqi Xu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
Lung Neoplasms
RBM10 Carcinogenesis Down-Regulation Mice Nude Adenocarcinoma of Lung Applied Microbiology and Biotechnology CTNNBIP1 Mice Cell Movement Cell Line Tumor medicine Wnt/β-catenin pathway Animals Humans Molecular Biology Wnt Signaling Pathway Ecology Evolution Behavior and Systematics beta Catenin Cell Proliferation Lung Chemistry Wnt signaling pathway RNA-Binding Proteins Cell Biology medicine.disease lung adenocarcinoma Xenograft Model Antitumor Assays medicine.anatomical_structure RNA-Binding Motif Tumor progression Catenin Cancer research Adenocarcinoma Female progression Developmental Biology Research Paper |
| Zdroj: | International Journal of Biological Sciences |
| ISSN: | 1449-2288 |
| Popis: | RNA-binding motif protein 10 (RBM10), one of the members of the RNA-binding protein (RBP) family, has a tumor suppressor role in multiple cancers. However, the functional role of RBM10 in lung adenocarcinoma (LUAD) and the underlying molecular mechanism remains unclear. In this study, we observed that RBM10 is significantly downregulated in LUAD tissues compared with normal tissues. Low RBM10 expression is significantly associated with poor outcome of LUAD patients. In vitro and in vivo experiments show that RBM10 inhibits cell proliferation, metastasis and EMT progression in LUAD. Mechanistically, we demonstrate that RBM10 interacts with β-catenin interacting protein 1 (CTNNBIP1) and positively regulates its expression, disrupting the binding of β-catenin to the transcription factor TCF/LEF, thereby inactivating the Wnt/β-catenin pathway. In conclusion, this is the first study reporting the role of RBM10 in suppressing LUAD progression at least via partly inactivating the Wnt/β-catenin pathway, which provides new insights into the tumorigenesis and metastasis of LUAD. Thus, RBM10 may be a promising new therapeutic target or clinical biomarker for LUAD therapy in the future. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|